13 completed. 13 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 13 | Completed 13 |
| Phase 2 | 1 | Completed 1 |
Follow Chronobiology Disorders: new trials by email Literature Review of Chronobiology Disorders trials Research Report on Chronobiology Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| THRIVE Feasibility Trial Anesthetic technique Propofol TIVA, Anesthetic technique inhaled agent - Surgery--Complications, Anesthesia Complication | Phase 3 | Completed | Washington University School of Medicine | 300 | 2022-09-29 | 2023-11-24 |
| Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) Tasimelteon, Placebo - Sleep Wake Disorders, Sleep Disorders, Circadian Rhythm | Phase 3 | Completed | Vanda Pharmaceuticals | 43 | 2020-12-09 | 2026-10-09 |
| The Clinical Utility of Measuring the Circadian Clock in Treatment of Delayed Sleep-Wake Phase Disorder Melatonin 0.5 MG, Dim Light Melatonin Onset (salivary) - Delayed Sleep Phase Syndrome | Phase 3 | Completed | University of Michigan | 44 | 2019-02-15 | 2022-11-25 |
| Diabetic Retinopathy: Effects of Melatonin Treatment on Visual Functions and Circadian Rhythm Melatonin 4 mg Tablet - Diabetic Retinopathy, Melatonin | Phase 3 | Completed | Glostrup University Hospital, Copenhagen | 31 | 2018-03-27 | 2021-08-02 |
| The Healthy Patterns Sleep Study Attention-Control Condition, Timed Activity Intervention - Dementia, Alzheimer Disease | Phase 3 | Completed | University of Pennsylvania | 421 | 2016-05-01 | 2024-07-26 |
| Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS tasimelteon, placebo - Smith-Magenis Syndrome, Circadian | Phase 2 / Phase 3 | Completed | Vanda Pharmaceuticals | 49 | 2015-09-01 | 2022-11-18 |
| Circadian Phase Adjustment and Improvement of Metabolic Control in Night Shift Workers Melatonin 2mg, Placebo - Sleep Disorders, Circadian Rhythm | Phase 3 | Completed | Universitätsklinikum Hamburg-Eppendorf | 46 | 2015-01-01 | 2017-05-25 |
| Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities Circadin 2/5/10 mg, Placebo - Sleep Disorders | Phase 3 | Completed | Neurim Pharmaceuticals Ltd. | 125 | 2013-10-01 | 2024-04-23 |
| Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception tasimelteon - Non-24-Hour Sleep-Wake Disorder | Phase 3 | Completed | Vanda Pharmaceuticals | 200 | 2011-10-01 | 2015-04-21 |
| Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder tasimelteon, Placebo - Non-24-Hour Sleep-Wake Disorder | Phase 3 | Completed | Vanda Pharmaceuticals | 20 | 2011-09-01 | 2014-10-10 |
| Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder tasimelteon, Placebo - Non-24-Hour Sleep-Wake Disorder | Phase 3 | Completed | Vanda Pharmaceuticals | 136 | 2010-08-01 | 2014-10-16 |
| Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD Armodafinil 150 mg/day, Placebo - Excessive Sleepiness, Shift Work Sleep Disorder | Phase 3 | Completed | Cephalon | 254 | 2004-03-01 | 2013-07-19 |
| Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep Disorder CEP-10953 (Armodafinil) - Narcolepsy, Sleep Apnea, Obstructive | Phase 3 | Completed | Cephalon | 328 | 2004-01-01 | 2013-07-19 |
Sleep Disorders, Circadian Rhythm (11) · Sleep Wake Disorders (6) · Blindness (3) · Disorders of Excessive Somnolence (3) · Dyssomnias (3) · Eye Diseases (3) · Nervous System Diseases (3) · Smith-Magenis Syndrome (2) · Alzheimer Disease (1) · Angelman Syndrome (1) · Autism Spectrum Disorder (1) · Cataplexy (1) · Cognitive Dysfunction (1) · Dementia (1)
Mental Disorders (12) · Occupational Diseases (11) · Nervous System Diseases (10) · Dyssomnias (8) · Neurologic Manifestations (7) · Pathological Conditions, Signs and Symptoms (7) · Signs and Symptoms (7) · Sleep Wake Disorders (6) · Sensation Disorders (3) · Sleep Disorders, Intrinsic (3) · Vision Disorders (3) · Abnormalities, Multiple (2) · Behavior (2) · Behavioral Symptoms (2)
tasimelteon (5) · Melatonin (4) · Modafinil (2) · Tablets (1)
Vanda Pharmaceuticals (5) · Cephalon (2) · Glostrup University Hospital, Copenhagen (1) · Neurim Pharmaceuticals Ltd. (1) · University of Michigan (1) · University of Pennsylvania (1) · Universitätsklinikum Hamburg-Eppendorf (1) · Washington University School of Medicine (1)
United States (10) · Germany (3) · Austria (1) · Denmark (1) · Finland (1) · France (1) · Italy (1) · Netherlands (1) · Russia (1) · United Kingdom (1)
Leslie Swanson, Ph.D. (1) · Michael S Avidan, MBBcH (1) · Nancy A. Hodgson (1) · Paul Gringras, PhD (1) · Rainer H Boeger, MD (1) · Robert Findling, MD (1) · Sachin Kheterpal, MD (1) · Shakoor Ba-Ali (1)
PMID 26466871, PMID 19880686, PMID 29096777, PMID 31982581, PMID 33853394, PMID 34344312, PMID 37068889, PMID 38033548, PMID 38445651, PMID 41950401
2015 (1), R01NR015226 (1)